RGNX on Nasdaq

REGENXBIO Inc.

We are a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Maze Therapeutics, Inc., Adaptimmune (United Kingdom) or Aerie Pharmaceuticals, or pick any stock.

  • TickerRGNX on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersRockville, Maryland1
  • Business address9804 Medical Center Drive, Rockville, Md 208502
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

We are a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our investigational gene therapies are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Through a single administration, gene therapy could potentially alter the course of disease significantly and deliver improved patient outcomes with long-lasting effects.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-94.6%Operating margin4
-113.8%Net margin4
104.5%Revenue growth, 20254
-188.7%Return on equity4
-$126.4MFree cash flow4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Zolgensma Royalties brought in 48% of the revenue REGENXBIO Inc. broke down this way in fiscal 2025.

  1. Zolgensma Royalties$82.5M448%up 1% from 2024
  2. Nippon Shinyaku Licenses$72.9M443%
  3. Nippon Shinyaku Services$11.8M47%
  4. Other Service Revenue$2.4M41%up 72% from 2024
  5. Itvisma royalties$641.0K40%
Products and services by year
Products and services20242025
Zolgensma Royalties$81.5M$82.5M
Nippon Shinyaku Licenses$72.9M
Nippon Shinyaku Services$11.8M
Other Service Revenue$1.4M$2.4M
Itvisma royalties$641.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$228.3M

Out of $170.4M in revenue.4 The company lost money this year.

Financial statements

Revenue56784$170.4M in 2025+384% since 2019
0$200.0M$400.0M$600.0M2019: $35.2M$35.2M20192020: $154.6M$154.6M2020+339%2021: $470.3M$470.3M2021+204%2022: $112.7M$112.7M2022−76%2023: $90.2M$90.2M2023−20%2024: $83.3M$83.3M2024−8%2025: $170.4M$170.4M2025+105%
Operating income56784-$161.2M in 2025+8% since 2019
-$400.0M-$200.0M0$200.0M2019: -$149.0M-$149.0M20192020: -$119.2M-$119.2M2020−20%2021: $160.0M$160.0M20212022: -$262.9M-$262.9M20222023: -$268.1M-$268.1M2023+2%2024: -$233.3M-$233.3M2024−13%2025: -$161.2M-$161.2M2025−31%
Net income56784-$193.9M in 2025+105% since 2019
-$400.0M-$200.0M0$200.0M2019: -$94.7M-$94.7M20192020: -$111.2M-$111.2M2020+17%2021: $127.8M$127.8M20212022: -$280.3M-$280.3M20222023: -$263.5M-$263.5M2023−6%2024: -$227.1M-$227.1M2024−14%2025: -$193.9M-$193.9M2025−15%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Revenues$170.4M$83.3M
Cost of license and royalty revenues$20.3M$33.6M
Research and development$228.3M$208.5M
General and administrative$82.9M$76.6M
Credit losses (recoveries)-$5.0M
Impairment of long-lived assets$2.1M
Other operating expenses$179.0K$865.0K
Total operating expenses$331.6M$316.7M
Loss from operations-$161.2M-$233.3M
Interest income from licensing$83.0K$174.0K
Investment income$12.2M$18.7M
Interest expense-$45.0M-$12.7M
Total other income (expense)-$32.7M$6.2M
Net loss-$193.9M-$227.1M
Unrealized gain on available-for-sale securities, net$54.0K$3.7M
Total other comprehensive income$54.0K$3.7M
Comprehensive loss-$193.8M-$223.4M
Net loss per share, basic-$3.76-$4.59
Net loss per share, diluted-$3.76-$4.59
Weighted-average common shares outstanding, basic51.6M shares49.5M shares
Weighted-average common shares outstanding, diluted51.6M shares49.5M shares

Compare REGENXBIO Inc. with another company

Leadership

Who has led REGENXBIO Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Kenneth T. Mills2016–2024
  2. Curran Simpson2024–now

President

  1. Kenneth T. Mills2016–2024

Chief financial officer

  1. Vittal Vasista2017–2024
  2. Mitchell Chan2024–now
20202025
Board members and other officers (26)

Former names

  • ReGenX Biosciences, LLCNov 7, 2013 to Nov 7, 20132

Timeline

  1. Jul 3, 2024New chief executive Curran Simpson becomes CEO12
  2. Feb 1, 2016New chief executive Kenneth T. Mills becomes CEO13

Filings

306 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 53 major events, 136 insider forms, 37 large holders, 60 other. The latest 20:

  1. Oct 13, 2026SCHEDULE 13G EDGAR
  2. Sep 23, 20268-K EDGAR
  3. Sep 3, 20264 PRIMARY DOCUMENT EDGAR
  4. Sep 3, 20264 PRIMARY DOCUMENT EDGAR
  5. Aug 27, 20264 PRIMARY DOCUMENT EDGAR
  6. Aug 27, 20263 PRIMARY DOCUMENT EDGAR
  7. Aug 25, 20268-K EDGAR
  8. Aug 24, 20268-K EDGAR
  9. Aug 6, 202610-Q EDGAR
  10. Aug 6, 20268-K EDGAR
  11. Aug 4, 20264 PRIMARY DOCUMENT EDGAR
  12. Aug 4, 20264 PRIMARY DOCUMENT EDGAR
  13. Jul 20, 20268-K EDGAR
  14. Jul 17, 2026424B5 EDGAR
  15. Jul 17, 2026FWP EDGAR
  16. Jul 16, 2026424B5 EDGAR
  17. Jul 6, 20264 PRIMARY DOCUMENT EDGAR
  18. Jul 6, 20264 PRIMARY DOCUMENT EDGAR
  19. Jul 6, 2026SC TO-I/A EDGAR
  20. Jul 1, 2026144 EDGAR

The 306 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

41 open-market trades by officers, directors and large owners since October 2021: 2 buys and 39 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 27, 2026Ciongoli Gregory AustinDirectorBuy53,407$9.36$499.9KForm 4
Aug 26, 2026Ciongoli Gregory AustinDirectorBuy49,196$9.14$449.7KForm 4
Jul 2, 2026PAKOLA STEVEChief Medical OfficerSale2,161$13.64$29.5KForm 4
Jul 1, 2026PAKOLA STEVEChief Medical OfficerSale36,725$12.86$472.3KForm 4
Jun 29, 2026PAKOLA STEVEChief Medical OfficerSale19,608$11.04$216.5KForm 4
May 11, 2026PAKOLA STEVEChief Medical OfficerSale15,309$11.02$168.7KForm 4
Mar 10, 2026PAKOLA STEVEChief Medical OfficerSale5,124$10.35$53.0KForm 4
Oct 9, 2025Simpson CurranChief Executive OfficerSale20,811$12.62$262.6KForm 4
Sep 29, 2025Simpson CurranChief Executive OfficerSale7,624$10.03$76.5KForm 4
Sep 10, 2025Simpson CurranChief Executive OfficerSale7,734$10.02$77.5KForm 4
May 12, 2025Mills Kenneth T.DirectorSale20,602$7.91$163.0KForm 4
Oct 1, 2024KARABELAS ARGERIS NDirectorSale10,000$10.11$101.1KForm 4
Sep 3, 2024KARABELAS ARGERIS NDirectorSale10,000$11.56$115.6KForm 4
Aug 1, 2024KARABELAS ARGERIS NDirectorSale10,100$13.51$136.5KForm 4
Aug 1, 2024Simpson CurranChief Executive OfficerSale100$15.00$1.5KForm 4
Jul 29, 2024KARABELAS ARGERIS NDirectorSale11,000$15.05$165.6KForm 4
Jul 29, 2024Simpson CurranChief Executive OfficerSale9,648$15.04$145.1KForm 4
Jul 25, 2024Mills Kenneth T.DirectorSale15,369$13.96$214.6KForm 4
Jul 24, 2024Mills Kenneth T.DirectorSale12,221$13.78$168.4KForm 4
Jul 17, 2024Mills Kenneth T.DirectorSale2,210$13.77$30.4KForm 4

All 41 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.6,397,440$76.6M0.0%+614,632
Redmile Group, LLC4,368,804$52.3M3.5%No change
State Street Corp2,971,173$35.6M0.0%+239,688
Jpmorgan Chase & Co2,214,169$26.2M0.0%−1,269,631
Vanguard Capital Management LLC2,107,557$25.2M0.0%+100,411
Morgan Stanley1,953,237$23.4M0.0%−112,920
Goldman Sachs Group Inc1,421,453$17.0M0.0%−418,010
Aqr Capital Management LLC1,378,358$16.5M0.0%+326,646
Vanguard Portfolio Management LLC1,355,554$16.2M0.0%+336,653
Marshall Wace, Llp1,284,950$15.4M0.0%New
Geode Capital Management, LLC1,241,296$14.9M0.0%+103,798
Integral Health Asset Management, LLC800,000$9.6M0.4%−700,000
Nuveen, LLC740,026$8.9M0.0%+158,010
Dimensional Fund Advisors LP731,586$8.8M0.0%−278,795
D. E. Shaw & Co., Inc.712,814$8.5M0.0%+426,813
Two Sigma Investments, LP669,808$8.0M0.0%+114,916
Citadel Advisors LLC669,023$8.0M0.0%New
Stifel Financial Corp560,727$6.7M0.0%+167,958
Bank Of America Corp /de/518,545$6.2M0.0%+193,685
22nw, LP492,759$5.9M5.6%No change
Millennium Management LLC480,762$5.8M0.0%+195,588
Pale Fire Capital SE466,209$5.6M0.4%−27,517
Northern Trust Corp421,839$5.1M0.0%+28,199
Charles Schwab Investment Management Inc396,450$4.7M0.0%+5,849
Lazard Asset Management LLC370,375$4.4M0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46